Challenges in Anemia in CKD

This activity is part of a series


Ajay K. Singh, MBBS, FRCP (UK), MBA
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program
Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/Dana Farber Cancer Institute
Boston, MA
Ajay K. Singh, MBBS, FRCP (UK), MBA

Ajay K. Singh, MBBS, FRCP, MBA, is a senior nephrologist at Brigham and Women’s Hospital in Boston, Massachusetts. He is the Senior Associate Dean for Postgraduate Medical Education at Harvard Medical School in Cambridge, Massachusetts as well as the Director of the Master of Medical Sciences in Clinical Investigation (MMSCI) program. He is the Co-PI for the Pathogen Genomics Centers of Excellence (PGCoE) Lead for Education.

Dr. Singh completed his undergraduate and medical training at the University College London School of Medicine in London, England. He moved to Boston in 1987 for his clinical and research renal fellowship at Tufts Medical Center and joined the Tufts University faculty in 1992. In 1998, he became the Clinical Director of the Renal Division and Director of Dialysis Services at Brigham and Women’s Hospital, one of the principal teaching hospitals of Harvard Medical School. He joined the faculty at HMS as an Associate Professor of Medicine.

Dr. Singh’s interests are in clinical research with a particular focus on the anemia of chronic kidney disease. He led groundbreaking studies in this field that include the CHOIR study, which was published in the New England Journal of Medicine. He served as a member of the steering committees for the TREAT and DRIVE studies. More recently, he has taken on the role of leading the ASCEND clinical development program — a phase III program of seven trials for the development of a novel prolyl hydroxylase inhibitor Daprodustat. Four of these trials have been published over the past year in the New England Journal of Medicine, JAMA Internal Medicine, and CJASN.

Dr. Singh is the author of over 160 original contributions and review articles, as well as the author/editor of 11 books on internal medicine and nephrology. He is a Fellow of the Royal College of Physicians in London.

Statement of Need

Anemia is chronically undermanaged in chronic kidney disease (CKD) patients and its etiology is poorly understood. Only 15% and 68% of CKD patients with anemia and severe anemia, respectively, received an official diagnosis; less than a quarter of diagnosed anemic patients and less than half of diagnosed severely anemic patients received treatment. The treatment goal of anemia is an increase in iron measures, yet safety concerns surround treatment options and leave guidelines nebulous. The benefits of options such as oral iron, intravenous iron, and erythropoiesis-stimulating agent (ESA) therapy must furthermore be balanced against significant adverse effects. A novel agent class known as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) expands anemia treatment options for dialysis-dependent (DD) CKD patients; its optimization, however, is reliant on adequate knowledge. It is thus imperative that clinicians are appraised on this emerging agent class.

In the second activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to utilize the latest data on novel therapies in clinical decision-making and guide learners through how best to address unmet needs in the treatment of anemia due to CKD.

Learning Objective

Utilize the latest data on novel therapies in clinical decision-making to address unmet needs in the treatment of anemia due to CKD

Financial Support

This educational activity is supported by an educational grant from GSK.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in nephrology or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-139-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Singh reports the following financial relationships:

Consultant: Allucent; Bayer; Chinook Therapeutics Inc.; Entrada Therapeutic, Inc.; GSK; Nephrology Times; and Zydus Pharmaceuticals, Inc.

Disclosures were obtained from the following CME Outfitters, LLC, staff, with no disclosures to report:

  • Jeffrey Helfand, DO (peer review)
  • Karla E. Crews, MSN, RN (peer review)
  • Keshia Pitt, PhD (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Challenges in Anemia in CKD
Event Date: 11/30/2023